Talha Badar
@talhabadarmd.bsky.social
Hematologist-Oncologist at Mayo Clinic. Interest in Acute Leukemia and Myeloid disorders.
Reposted by Talha Badar
👇🏽 Trial finding that led to approval:
Menin inhibitor revumenib showed promising efficacy in R/R NPM1-mutated AML — CR + CRh = 23%, ORR ≈ 47%, median DOR ~ 4.7 mo, manageable QTc prolongation.
📈 Led to FDA approval (2025) for R/R NPM1m AML.
#AML #Revumenib #MeninInhibitor doi.org/10.1182/blood.…
Menin inhibitor revumenib showed promising efficacy in R/R NPM1-mutated AML — CR + CRh = 23%, ORR ≈ 47%, median DOR ~ 4.7 mo, manageable QTc prolongation.
📈 Led to FDA approval (2025) for R/R NPM1m AML.
#AML #Revumenib #MeninInhibitor doi.org/10.1182/blood.…
October 26, 2025 at 3:28 PM
👇🏽 Trial finding that led to approval:
Menin inhibitor revumenib showed promising efficacy in R/R NPM1-mutated AML — CR + CRh = 23%, ORR ≈ 47%, median DOR ~ 4.7 mo, manageable QTc prolongation.
📈 Led to FDA approval (2025) for R/R NPM1m AML.
#AML #Revumenib #MeninInhibitor doi.org/10.1182/blood.…
Menin inhibitor revumenib showed promising efficacy in R/R NPM1-mutated AML — CR + CRh = 23%, ORR ≈ 47%, median DOR ~ 4.7 mo, manageable QTc prolongation.
📈 Led to FDA approval (2025) for R/R NPM1m AML.
#AML #Revumenib #MeninInhibitor doi.org/10.1182/blood.…
Reposted by Talha Badar
AML-defining cytogenetic and molecular abnormalities (regardless of blast count)between the WHO 5th Edition (2022) and the International Consensus Classification (ICC 2022). #leusm #MedTwitter #hemonctrainees #when_on_service 👇🏽
October 29, 2025 at 9:25 PM
AML-defining cytogenetic and molecular abnormalities (regardless of blast count)between the WHO 5th Edition (2022) and the International Consensus Classification (ICC 2022). #leusm #MedTwitter #hemonctrainees #when_on_service 👇🏽
AML-defining cytogenetic and molecular abnormalities (regardless of blast count)between the WHO 5th Edition (2022) and the International Consensus Classification (ICC 2022). #leusm #MedTwitter #hemonctrainees #when_on_service 👇🏽
October 29, 2025 at 9:25 PM
AML-defining cytogenetic and molecular abnormalities (regardless of blast count)between the WHO 5th Edition (2022) and the International Consensus Classification (ICC 2022). #leusm #MedTwitter #hemonctrainees #when_on_service 👇🏽
Olutasidenib alone or combined with azacitidine in pts with IDH1m MDS ashpublications.org/bloodadvances/…
👉🏾 PI/II data, Oluta show ORR (59%), CR ~27%, mDOR 14.6 mo & CR duration 20.5 mo; mOS 27.2 mo (n≈19)
👉🏾 cross-trial comparison; Ivo in MDS (image 2) ORR was 83% CR 39%, &mDOR NR, mOS 36 m#mdsds
👉🏾 PI/II data, Oluta show ORR (59%), CR ~27%, mDOR 14.6 mo & CR duration 20.5 mo; mOS 27.2 mo (n≈19)
👉🏾 cross-trial comparison; Ivo in MDS (image 2) ORR was 83% CR 39%, &mDOR NR, mOS 36 m#mdsds
https://ashpublications.org/bloodadvances/…
October 29, 2025 at 11:47 AM
Olutasidenib alone or combined with azacitidine in pts with IDH1m MDS ashpublications.org/bloodadvances/…
👉🏾 PI/II data, Oluta show ORR (59%), CR ~27%, mDOR 14.6 mo & CR duration 20.5 mo; mOS 27.2 mo (n≈19)
👉🏾 cross-trial comparison; Ivo in MDS (image 2) ORR was 83% CR 39%, &mDOR NR, mOS 36 m#mdsds
👉🏾 PI/II data, Oluta show ORR (59%), CR ~27%, mDOR 14.6 mo & CR duration 20.5 mo; mOS 27.2 mo (n≈19)
👉🏾 cross-trial comparison; Ivo in MDS (image 2) ORR was 83% CR 39%, &mDOR NR, mOS 36 m#mdsds
Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML ashpublications.org/bloodadvances/… #Agile_study:mOSOS 24 mo.#cross-trialal comparison; VIALE-A trial mOS IDH2-m AML ( 27.5 vs 13 mo) & IDH1-m AML (median 10.2 vs 2.2 mo#leusms#AMLML
October 29, 2025 at 11:24 AM
Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML ashpublications.org/bloodadvances/… #Agile_study:mOSOS 24 mo.#cross-trialal comparison; VIALE-A trial mOS IDH2-m AML ( 27.5 vs 13 mo) & IDH1-m AML (median 10.2 vs 2.2 mo#leusms#AMLML
👇🏽 Trial finding that led to approval:
Menin inhibitor revumenib showed promising efficacy in R/R NPM1-mutated AML — CR + CRh = 23%, ORR ≈ 47%, median DOR ~ 4.7 mo, manageable QTc prolongation.
📈 Led to FDA approval (2025) for R/R NPM1m AML.
#AML #Revumenib #MeninInhibitor doi.org/10.1182/blood.…
Menin inhibitor revumenib showed promising efficacy in R/R NPM1-mutated AML — CR + CRh = 23%, ORR ≈ 47%, median DOR ~ 4.7 mo, manageable QTc prolongation.
📈 Led to FDA approval (2025) for R/R NPM1m AML.
#AML #Revumenib #MeninInhibitor doi.org/10.1182/blood.…
October 26, 2025 at 3:28 PM
👇🏽 Trial finding that led to approval:
Menin inhibitor revumenib showed promising efficacy in R/R NPM1-mutated AML — CR + CRh = 23%, ORR ≈ 47%, median DOR ~ 4.7 mo, manageable QTc prolongation.
📈 Led to FDA approval (2025) for R/R NPM1m AML.
#AML #Revumenib #MeninInhibitor doi.org/10.1182/blood.…
Menin inhibitor revumenib showed promising efficacy in R/R NPM1-mutated AML — CR + CRh = 23%, ORR ≈ 47%, median DOR ~ 4.7 mo, manageable QTc prolongation.
📈 Led to FDA approval (2025) for R/R NPM1m AML.
#AML #Revumenib #MeninInhibitor doi.org/10.1182/blood.…
